Cytek's analyzer category sales were up more than 30% compared to a year ago, and gross margin improved 600 basis points from the Singapore manufacturing shift, lower tariffs and better material costs.
CTKB · Cytek Biosciences, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
SciTech Biosciences reported third-quarter revenue of $53.2 million, up 2% year-over-year, and GAAP gross margin of 59%. Full-year 2026 revenue guidance was narrowed to $208 million to $211 million, with adjusted EBITDA expected around break-even.
Cytek Biosciences reported nine-month revenue of $145.5 million, up 4%, while net loss widened to $37.1 million from $22.5 million; service revenue rose 13% and gross margin reached 56%.
Cytek Biosciences reported third-quarter revenue of $53.2 million, up 2%, GAAP gross margin of 59% and a net loss of $6.1 million; full-year revenue guidance was narrowed to $208 million to $211 million.
On September 23, 2026, Cytek Biosciences, Inc. adopted amended and restated bylaws, expanding proponent disclosure and certifications, incorporating universal proxy rules, and adding special-meeting nomination procedures.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 4, 2026TL;DR. Revenue guidance retained its midpoint, while gross margin expanded, high-end instrument demand remained strong and recurring revenue increased. APAC and biopharma sales declined, adjusted EBITDA fell, patent litigation remained unresolved, and the organizational restructuring was postponed.
- + GAAP gross margin increased to 59% from 53%, supported by higher product and service gross margins.
- + Full-year 2026 revenue guidance retained its midpoint while the range narrowed to $208 million–$211 million.
- + Demand for high-end Full Spectrum Profiling instruments remained strong, with Aurora and Aurora Evo placements up 23% year over year.
- + Recurring revenue reached $19.1 million and increased to 36% of trailing-12-month revenue from 33%.
- + The installed base expanded to 4,073 instruments after adding 140 units during the quarter.
- + Management expects a seasonally stronger fourth quarter and full-year adjusted EBITDA around break-even.
- − APAC revenue, including China, fell 25% year over year, although it increased 5% sequentially from Q2.
- − Biopharma distributor and CRO revenue declined approximately 17% to $28.7 million, and product revenue fell 3%.
- − Adjusted EBITDA fell to $0.7 million from $2.5 million.
- − The jury found infringement under the doctrine of equivalents on the fourth patent claim, and the company is pursuing remedies.
- − General and administrative expense increased 14%, primarily because of higher litigation-related expenses.
- − Implementation of the new business-unit structure was postponed until the start of 2027 because the mid-year transition was viewed as too risky.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $1.5M | Q2 2026 | — |
| Net new units added | 142 | Q2 2026 | — |
| Non-GAAP adjusted gross margin non-GAAP | 56% | Six Months Ended June 30, 2026 | — |
| Non-GAAP adjusted gross profit non-GAAP | $52.04M | Six Months Ended June 30, 2026 | — |
| Total installed base | 3,933 | Q2 2026 | — |
| Total recurring revenue | $18.5M | Q2 2026 | — |
| Trailing-12-month recurring revenue as a percentage of total revenue | 35% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CTKB
this stock
Cytek Biosciences, Inc.
|
$774.24M | +17.2% | +6414.2% | — | 3.1% |
|
ABT
Abbott Laboratories
|
$180.95B | -16.6% | +5.7% | 39.0 | 1.1% |
|
MDT
Medtronic plc
|
$128.83B | +4.9% | +8.4% | 24.8 | 1.8% |
|
SYK
Stryker Corp
|
$121.12B | -9.5% | +11.2% | 33.9 | 1.7% |
|
BSX
Boston Scientific Corp
|
$63.26B | -54.2% | +12.5% | 18.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 20
Cytek's analyzer category sales were up more than 30% compared to a year ago, and gross margin improved 600 basis points from the Singapore manufacturing shift, lower tariffs and better material costs.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CTKB | +2.8% | +7.6% | +41.3% | -3.4% | +17.2% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +6.7% | +13.2% | +44.8% | -0.1% | +10.2% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.